Celgene just hit a major setback with its next blockbuster drug

  • Celgene said Tuesday that the FDA refused to review its multiple sclerosis drug Ozanimod for approval.
  • “Upon its preliminary review, the FDA determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review,” Celgene said in a news release. NDA is short for new drug application.
  • Ozanimod, if approved, is expected to make as much as $US2 billion in peak sales.
  • Celgene has had a difficult couple of months. In October 2017, the company had a huge earnings flop. The company’s also made two acquisition deals in 2018 so far, but the news hasn’t been enough to excite investors.
  • Celgene’s stock fell as much as 6% in pre-market trading on Wednesday.

Screen Shot 2018 02 28 at 9.15.40 AMMarkets Insider

NOW WATCH: Money & Markets videos

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.